
vTv Therapeutics Inc. Class A Common Stock
VTVT
VTVT: vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. The company lead program is TTP399, an orally administered, small molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes.
moreShow VTVT Financials
Recent trades of VTVT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by VTVT's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on VTVT's company Twitter account
Number of mentions of VTVT in WallStreetBets Daily Discussion
Recent insights relating to VTVT
Recent picks made for VTVT stock on CNBC
ETFs with the largest estimated holdings in VTVT
Flights by private jets registered to VTVT